Suma S. Rao
Singapore, Singapore
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants.
Journal: Human vaccines & immunotherapeutics
Published: May 05, 2026
Posterior reversible encephalopathy syndrome in dengue virus infection with concurrent encephalitis and ischemic stroke: a case report.
Journal: BMC infectious diseases
Published: December 23, 2025
Immunogenicity of high-dose recombinant influenza vaccine versus standard-dose egg-grown and cell-grown vaccines among frequently and infrequently vaccinated young adults in Singapore: a randomised, controlled, double-blind, single-centre, phase 4 clinical trial.
Journal: The Lancet. Infectious diseases
Published: September 16, 2025
Modeling Antibody Kinetics Post-mRNA Booster Vaccination and Protection Durations Against SARS-CoV-2 Infection.
Journal: Journal of medical virology
Published: February 13, 2025
Severe invasive infections linked to IRAK2 immune variants.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: May 15, 2024
Convalescent plasma for the treatment of patients with COVID-19: the Singapore experience and lessons learnt.
Journal: Singapore medical journal
Published: April 08, 2024
Imprinting of IgA responses in previously infected individuals receiving bivalent mRNA vaccines (WT and BA.4/BA.5 or WT and BA.1).
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: March 11, 2024
First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial.
Journal: EBioMedicine
Published: March 01, 2024
Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial.
Journal: Vaccine
Published: September 07, 2023
Variant-Specific IgA Protects Against Omicron Infection.
Journal: The Journal of infectious diseases
Published: September 01, 2023
Heterologous mRNA vaccine boosters induce a stronger and longer-lasting antibody response against Omicron XBB variant.
Journal: The Lancet regional health. Western Pacific
Published: December 15, 2022
Efficient recall of SARS-CoV-2 variant-reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boosters.
Journal: Journal of medical virology
Published: July 07, 2022
Last Updated: 09/26/2026